Chronic Lower Back Pain Market Forecast, 2036 | Industry Set for Steady Growth as Regenerative Medicine and Opioid Alternatives Drive Innovation

Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Chronic Lower Back Pain - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The chronic lower back pain (CLBP) market across the seven major markets (7MM)-the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan-was valued at approximately USD 9.70 billion in 2025. The market is forecast to expand at a compound annual growth rate of approximately 5.4% from 2026 to 2036, supported by increasing disease prevalence, population aging, rising obesity rates, sedentary lifestyles, and continued innovation in non-opioid and disease-modifying treatments.

The United States represented the largest regional market, generating approximately USD 6.60 billion in 2025. It also accounted for nearly half of the 148 million prevalent CLBP cases identified across the 7MM. Total Fina Elf prevalent cases are projected to rise at a CAGR of approximately 0.8% through 2036, reflecting the growing burden of degenerative spinal disorders and improved recognition of chronic pain conditions.

Chronic Lower Back Pain Epidemiology and Patient Burden

CLBP creates a substantial clinical and socioeconomic burden through persistent pain, recurrent flare-ups, physical disability, reduced mobility, and long-term activity limitations. U.S. survey data from 2022 indicated that approximately 28% of adults experienced CLBP. In 2025, the United States recorded an estimated 76 million prevalent cases, with adults aged 70 years and older accounting for approximately 22 million cases.

Moderate CLBP represented the largest severity segment in the United States at approximately 50% of cases, followed by mild disease at 30% and severe disease at 20%. Although severe CLBP comprised the smallest segment, these patients generally required more intensive treatment and generated higher healthcare utilization. Approximately 32 million moderate-to-severe cases and 6 million mild cases were treated in the United States in 2025.

Degenerative disc disease (DDD) remains a leading contributor to CLBP, driven by age-related degeneration and cumulative mechanical stress. A clinically important subgroup of patients with moderate-to-severe disease also presents with Modic Type 1 changes, an inflammatory vertebral endplate phenotype associated with persistent pain and poorer clinical outcomes.

Current CLBP Treatment Landscape

CLBP management is multimodal and generally combines exercise, physiotherapy, patient education, weight management, and pharmacological treatment. Frequently used medicines include nonsteroidal anti-inflammatory drugs, acetaminophen, duloxetine, corticosteroids, muscle relaxants, neuropathic agents, and selected opioids. Epidural injections, neuromodulation, minimally invasive procedures, and surgery may be considered according to disease severity, underlying pathology, and response to previous treatment.

Opioids accounted for approximately 30% of CLBP treatment use in the United States in 2025, indicating continued reliance on opioid analgesics for persistent or refractory pain. Marketed options for severe chronic pain include XTAMPZA ER, Collegium Pharmaceutical's abuse-deterrent extended-release oxycodone formulation, and BELBUCA, a buprenorphine buccal film. However, concerns regarding dependence, adverse effects, and long-term safety continue to accelerate demand for non-opioid alternatives.

The current market remains heavily influenced by generic therapies. Estimated annual treatment costs were approximately USD 78 for commonly used nonsteroidal anti-inflammatory drugs and USD 189 for selected opioids. While these therapies are widely accessible, their limited durability and predominantly symptomatic effects leave significant room for differentiated treatments.

Key Chronic Lower Back Pain Market Drivers

• Increasing prevalence and population aging: Growth in degenerative spinal disease, obesity, sedentary behavior, and age-related musculoskeletal conditions is expanding the addressable patient population.
• Demand for non-opioid therapies: Clinical guidelines and safety concerns are encouraging greater use of non-opioid pharmacological treatments, regenerative medicine, neuromodulation, and minimally invasive interventions.
• Advances in personalized pain management: Improved patient stratification and targeted treatment selection may support better outcomes in heterogeneous CLBP populations.
• Expansion of regenerative medicine: Cell and gene therapies are being developed to promote disc regeneration, tissue repair, neuroprotection, and disease modification.
• Need for durable outcomes: Patients, physicians, and payers increasingly prioritize sustained pain reduction, improved physical function, and fewer repeated interventions.

Emerging CLBP Therapies and Pipeline Outlook

The chronic lower back pain pipeline is shifting toward non-opioid, regenerative, anti-inflammatory, metabolic, and disease-modifying approaches. Intradiscal injection remains a prominent delivery route for regenerative therapies because it enables direct treatment of degenerated discs. Developers are also evaluating systemic and minimally invasive approaches intended to improve accessibility and treatment durability.

Rexlemestrocel-L, developed by Mesoblast in collaboration with Grunenthal, is a Phase III cell therapy for moderate-to-severe CLBP associated with DDD. Administered through a single intradiscal injection, the therapy is intended to address underlying disc pathology. Clinical findings have indicated sustained pain reduction for up to 36 months in selected patients. In July 2026, Mesoblast announced that at least 300 patients had been treated in the pivotal Phase III MSB-DR004 trial.

DiscGenics is developing rebonuputemcel, also known as IDCT, as an allogeneic regenerative cell therapy for lumbar DDD. Its Phase III PIVOT and CONFIRM programs are designed to evaluate whether treatment can deliver durable improvements beyond symptomatic pain control. In June 2026, an independent Data and Safety Monitoring Board recommended continuation of the Phase III study without protocol modifications following a planned safety review.

VERTANICAL's VER-01, or EXILBY, is an investigational non-opioid therapy derived from a standardized full- Spectrum Cannabis sativa extract. The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to VER-01 for CLBP in May 2026. The company subsequently initiated an additional pivotal U.S. Phase III trial, with an initial data readout anticipated in 2027 and a potential New Drug Application planned for 2028, subject to positive results.

Other pipeline programs include SP-102 (SEMDEXA), BRTX-100, olastrocel, KLS-2031, PP353, HYDRAFIL, cebranopadol, and retatrutide. These candidates Target pain, inflammation, disc degeneration, neuropathic mechanisms, metabolic risk factors, or tissue repair. PP353 is being evaluated for patients with Modic Type 1 changes, while retatrutide is being studied in patients with overweight or obesity and CLBP.

Development risks remain significant. In August 2025, Spine BioPharma reported that the Phase III MODEL trial of SB-01 did not meet its primary endpoint at Month 6 compared with sham control. Across the pipeline, high placebo responses, patient heterogeneity, manufacturing complexity, long-term safety requirements, reimbursement challenges, and the need to demonstrate durable functional improvement may affect regulatory and commercial outcomes.

Competitive Landscape and Leading Companies

Companies active in the chronic lower back Pain Therapeutics market include VERTANICAL, Collegium Pharmaceutical, Eli Lilly, Scilex Holding and Semnur Pharmaceuticals, Spine BioPharma, DiscGenics, Mesoblast, Grunenthal, Tris Pharma and Adneuris Therapeutics, BioRestorative Therapies, Vertex Pharma Pharmaceuticals, and Stayble Therapeutics.

Commercial uptake of emerging CLBP treatments will depend on efficacy, durability, safety, administration route, physician familiarity, patient selection, reimbursement, and cost-effectiveness. Minimally invasive therapies that integrate into established interventional pain pathways may achieve faster adoption. Cell and gene therapies may experience more gradual uptake as physicians and payers evaluate long-term outcomes, manufacturing consistency, and real-world value.

Unmet Needs and Market Opportunities

• Limited long-term efficacy of existing pharmacological therapies
• Continued reliance on opioids for persistent and refractory pain
• Variable treatment response across heterogeneous patient populations
• Diagnostic uncertainty and weak correlation between imaging findings and symptoms
• Need for validated biomarkers and improved patient selection
• Limited access to advanced and minimally invasive treatments
• Demand for durable therapies that improve both pain and physical function

Report Coverage and Strategic Insights

The report examines historical and forecast epidemiology, treatment practices, market size, therapy share, patient uptake, pricing, reimbursement, and competitive developments across the 7MM from 2022 to 2036. It includes profiles of marketed and investigational therapies, clinical development analysis, patent and partnership reviews, market access considerations, and country-level forecasts.

The analysis incorporates epidemiology-based bottom-up forecasting, SWOT analysis, conjoint analysis, patient journey assessment, and insights from key opinion leaders and subject matter experts. More than 10 experts were contacted, with interviews conducted with over six specialists across the 7MM, including representatives associated with leading academic and clinical institutions.

The report supports pharmaceutical companies, biotechnology developers, investors, healthcare providers, and market access teams seeking to evaluate the CLBP treatment landscape. Key areas include patient population forecasts, therapeutic market opportunities, pipeline prioritization, expected drug uptake, peak patient share, pricing trends, reimbursement barriers, and the commercial potential of regenerative and disease-modifying therapies.

Overall, the chronic lower back pain market is expected to grow steadily through 2036. Rising patient numbers, persistent unmet need, efforts to reduce opioid dependence, and progress in regenerative medicine are reshaping the competitive landscape. Therapies that demonstrate durable pain relief, meaningful functional improvement, acceptable safety, and clear cost-effectiveness are likely to be best positioned for clinical adoption and long-term commercial success.

A selection of companies mentioned in this report includes, but is not limited to:

• VERTANICAL
• Collegium Pharmaceutical
• Eli Lilly
• Scilex Holding (Semnur Pharmaceuticals)
• Spine BioPharma
• DiscGenics
• Mesoblast
• Grunenthal
• Tris Pharma (Adneuris Therapeutics)
• BioRestorative Therapies
• Afasci
• Vertex Pharma Pharmaceuticals
• Stayble Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/gft8fg

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900